Laserfiche WebLink
i <br />i <br />1. <br />i <br />i <br />against ParmystsaPa y <br />to WHWM4, Ift FW my <br />set any reasonable costs, including <br />reasonable attorneys' feend expenses, arising -lb amysuch action. <br />Rebate amounts aid to Client ursuatdaQ this A eem tended to be treat" "tfWounts" pursuant <br />, <br />p P.m P <br />lathe federalanEl-kicskback statute;01 � 01i 1*, p i lamenting regulations. Client is obligated <br />ifrequested by the SocreteryoftheUnited States Departmett .41"th atttl'iiuman Services, or as otherwise required . . <br />by applicable lave, to vepott the Rebate amounts and to provi$t; t copy 9fthis noticm 50 will refrain from doing <br />anything that would impede CH0q**m meeting any such obligation. <br />Ii�'s ttAt�ioa Ptga krtsgrtteit ! , :. <br />B!$I is pleased to offer our Inflatitist Protection Prograttt to Y60r`Under the program, ESI will pay to <br />f <br />Sponsor $2.00 per Formulary Brattdi3rug claim (the "Sponsor Inflation Payment'). Subject to the conditions set forth i <br />(B$,Ishall �reponsorthe Sponsor Inflation Payment 4pproximsioly olinl andeighity{l dtt <br />following the end of each calendar quarter for utilization occurring during such qui: l rmulaY'r& <br />be excluded. <br />Terms and CondWons of the Inflation Protection.ftg= <br />P <br />The following claims will be excluded frvrtt a31 Wonlat%s veWd'to the Inflation Protection Program: Medicare <br />claims, Medicaid claims, any other government health care program claims, OTCs, member submitted claims, <br />subrogation claims compounds, Generic Drugs, claims submitW*—Sponsor owned, im <br />pharmacies, 340B claims, claims submitted through a 100% member east -share program, Biosimilars, drugs where <br />the quantity or packaging has been changed bythe manufacturer from the past year, and drugs for which there was <br />no utilization in the calendaryeatptl[ulrbtx'b�Cat yam`sWvAw ltdlon Guarantee payment is being <br />• determined. <br />;flloonsor makes material changes to itslamulary or benefit design that negatively impacda 'iAllity too <br />ikon relative to Sponsor's Formulary drug mix, then ESI reserves the right to make at► il!t 1.0 <br />tai Inflation Guarantee.. <br />ESrs Inflation Protection Pmt and the underlying economics, is sc 1 awtl from, rebates and <br />ttttntufechMadrmWlW-Stine 411 addition to any rebate <br />payments to whirl► Sponsor is ei'tfttled.**be to t".fir mooft ttdWd to drug price <br />in utift qtr a salmi guarantee either *W as sot above. <br />The tbllowing prWogasmmpOoas $W apply fotr'Pn. — oses of this ,greement: <br />I. If CheatdttWes to implemerd a miy generic, mandatok, nai 1, step therapy ior other program dwingThe <br />Term. F-1wagreed that proposed prWft terms other than ta%W`guarantees will remain unchanged. <br />2. ?SI must agree to propose pricing based on its broad national retail network that dudes all major national <br />and -.regional phi chains. <br />3. Pricing is not based upon the assumption that EST will be the &KrJ siivc PBM. C reserves the right to <br />purchase specialty products from other sources. Clietd +tai mow► f a.tiption m art t tw Witte i:. . <br />specialty provider. Additionally,Adrtami tt tan will work vift CItent as needed to i*, direct specialty l <br />;. <br />.i <br />m e-dications to A praftred provider: <br />DISCOUNTS ...... <br />4. ThtspoposW "effective" =4g& disc4tlult and 'dw gg . AMW <br />.. >l Sso <br />WaaE . : <br />Efatusries <br />MAC i(knerics <br />ShWe SturesGenerics i. <br />i!1t)rr:it i1'I" I. i REIN IS CONFIDENTIAL, PRd")Mi. <br />4101- 1, OX MAW WXP.AND RxBENEFITS 04^w <br />